Search results
Author(s):
Noel S Lee
,
Lori B Daniels
Added:
3 years ago
Today, natriuretic peptides are ubiquitously utilized for the diagnosis, treatment, and prognostication of heart failure in the Emergency Department, as well as inpatient and outpatient settings alike.1–5 These endogenous hormones counteract some of the most detrimental effects of heart failure. Given their clinical and physiological importance, the fact that a manuscript describing the…
View more
Foreword
Author(s):
Andrew JS Coats
,
Giuseppe Rosano
Added:
3 years ago
Article
Author(s):
Sam Hayman
,
John J Atherton
Added:
3 years ago
Heart failure (HF) is associated with significant morbidity and mortality and confers a major economic burden.1 Large randomised controlled trials (RCTs) have demonstrated that inhibition of the renin–angiotensin– aldosterone and sympathetic nervous systems improve outcomes in patients with HF and a reduced left ventricular ejection fraction (HFrEF) (see Figure 1),2–9 with clinical guidelines…
View more
Author(s):
Mohammad S Alzahri
,
Anita Rohra
,
W Frank Peacock
Added:
3 years ago
Acute heart failure (AHF) presents symptoms primarily the result of pulmonary congestion due to elevated left ventricular (LV) filling pressures with or without reduced ejection fraction (EF). Common precipitating pathology includes coronary artery disease (CAD), hypertension and valvular heart diseases, in addition to other noncardiac conditions, such as diabetes, anaemia and kidney dysfunction…
View more
Author(s):
Ovidiu Chioncel
,
Sean P Collins
,
Andrew P Ambrosy
,
et al
Added:
3 years ago
Acute heart failure (AHF) is a heterogeneous clinical syndrome including diverse phenotypes sharing similar presenting signs and symptoms.1 The diversity of aetiologies and precipitants of HF and their specific pathophysiologic mechanisms, may result in distinct clinical profiles requiring specific treatment approaches.
Pulmonary oedema (PO) is a common manifestation of AHF associated with a…
View more
Inotropes in Acute Heart Failure
Author(s):
Vasiliki Bistola
,
Angelos Arfaras-Melainis
,
Eftihia Polyzogopoulou
,
et al
Added:
3 years ago
Article
Author(s):
Bao Tran
,
Gregg C Fonarow
Added:
3 years ago
Heart failure (HF) remains a major public health problem resulting in substantial morbidity, mortality and healthcare expenditures globally. The European Society of Cardiology (ESC) 2012 Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure and the American College of Cardiology Foundation (ACCF)/American Heart Association (AHA) 2013 Guideline for the Management of Heart…
View more
Author(s):
Juan Tamargo
Added:
3 years ago
Chronic heart failure (HF) is a complex and progressive clinical syndrome resulting from any abnormality of cardiac structure or function. The American College of Cardiology Foundation/American Heart Association guideline defines HF as ‘a complex clinical syndrome that results from any structural or functional impairment of ventricular filling or ejection of blood’.1 The European Society of…
View more
Author(s):
Ingibjörg Kristjánsdóttir
,
Tonje Thorvaldsen
,
Lars H Lund
Added:
3 years ago
From Acute Heart Failure Towards Worsening or De Novo Heart Failure
The natural history of heart failure (HF) is characterised by disease progression and episodes of worsening HF and acute decompensation requiring outpatient treatment intensification, emergency department or in-hospital care.
Acute HF (AHF), also known as acute decompensated HF, is defined as a progressive and sometimes rapid…
View more
Author(s):
Nicholas Wettersten
,
Alan S Maisel
Added:
3 years ago
Cardiac troponin (cTn) is the core biomarker for the diagnosis of a myocardial infarct (MI).1 Indeed, as stated in Table 1, it meets all the definitions of a biomarker for acute coronary syndrome (ACS), as suggested by Maisel.2 In the setting of ACS, in addition to its diagnostic use, it is prognostic, clinically actionable and can be monitored during therapy as a surrogate of improvement. In…
View more